Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary experience with ipilimumab treatment outside of clinical trials to determine the frequency of use of systemic corticosteroid or anti...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 33; no. 28; p. 3193
Main Authors:	Horvat, Troy Z, Adel, Nelly G, Dang, Thu-Oanh, Momtaz, Parisa, Postow, Michael A, Callahan, Margaret K, Carvajal, Richard D, Dickson, Mark A, D'Angelo, Sandra P, Woo, Kaitlin M, Panageas, Katherine S, Wolchok, Jedd D, Chapman, Paul B
Format:	Journal Article
Language:	English
Published:	United States 01.10.2015
Subjects:	Adrenal Cortex Hormones - therapeutic use Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antineoplastic Agents - adverse effects Disease-Free Survival Drug Substitution Female Humans Immunosuppressive Agents - therapeutic use Ipilimumab Kaplan-Meier Estimate Male Medical Records Melanoma - drug therapy Melanoma - immunology Melanoma - mortality Melanoma - secondary Middle Aged New York City Retrospective Studies Risk Factors Skin Neoplasms - drug therapy Skin Neoplasms - immunology Skin Neoplasms - mortality Skin Neoplasms - pathology Time Factors Treatment Failure Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - immunology Young Adult
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!